We advised Roche on the Rule 144A / Regulation S offering comprising five tranches of notes

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A / Regulation S offering of $1.25 billion aggregate principal amount of 1.882% notes due 2024, $1 billion aggregate principal amount of 2.132% notes due 2025, $1.25 billion aggregate principal amount of 2.314% notes due 2027, $750 million aggregate principal amount of floating-rate notes due 2023 and $750 million aggregate principal amount of floating-rate notes due 2025, guaranteed by Roche Holding Ltd.

Headquartered in Basel, Switzerland, the Roche Group is a leading international research-based healthcare group with two operational divisions: pharmaceuticals and diagnostics. These divisions offer products for screening and early detection, prevention, diagnosis of disease, treatment and treatment monitoring. The Roche Group operates in more than 100 countries and employs more than 100,000 people worldwide.

The Davis Polk corporate team included partner Leo Borchardt and associates Christopher Diel and Tanu Sinha. Counsel Alon Gurfinkel and associate Veronica Davis provided tax advice. All members of the Davis Polk team are based in the London office.

Copy link to share post